Target intelligence / Profile preview

Aminotransferase enzyme dependent on pyridoxal phosphate

Molecular classification
Enzyme, Transferase, Pyridoxal-phosphate-dependent enzyme
01

Overview

Aminotransferases dependent on pyridoxal phosphate are a large family of enzymes that catalyze the transfer of an amino group from an amino acid to a keto acid—a process known as transamination. These enzymes require pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, as a coenzyme. PLP acts both as an electron sink and electrophilic catalyst during these reactions by forming a Schiff base with substrate molecules at the enzyme's active site. This enables stabilization and transformation of reaction intermediates critical for biosynthesis and degradation pathways involving most natural amino acids. The activity and specificity depend on both protein structure—especially residues involved in π–π stacking with PLP—and proper binding pocket formation[1][2]. Dysfunction or inhibition can lead to significant metabolic disturbances affecting neurological health, liver function, and overall nitrogen balance in humans[2][3].

Other names
PLP-dependent aminotransferasePyridoxal 5'-phosphate-dependent aminotransferaseTransaminase (when referring to the class of enzymes)
02

Mechanism of action

Drugs or compounds that inhibit these enzymes typically act by binding to the active site and preventing transamination reactions, often by mimicking substrate or cofactor structure.

03

Biological functions

Amino acid metabolism (transamination)Biosynthesis and degradation of amino acidsNitrogen metabolismElectron sink for carbanion stabilization
04

Disease associations

Neurological disorders (due to vitamin B6/PLP deficiency)Inborn errors of amino acid metabolism (e.g., primary hyperoxaluria, some forms of epilepsy)Liver disease
05

Safety considerations

Inhibition can disrupt essential amino acid metabolism.Vitamin B6 deficiency impairs function, leading to neurological symptoms.Off-target effects could impact multiple metabolic pathways due to the broad role in amino acid processing.
06

Interacting drugs

There are no widely used direct drugs targeting aminotransferases as a therapeutic mechanism, but inhibitors or modulators exist in research settings. Some drugs may affect PLP levels indirectly, such as isoniazid (which can cause vitamin B6 deficiency).
07

Biomarkers

Elevated serum levels of specific aminotransferases—such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST)—are clinical biomarkers for liver injury or disease.

Beyond the preview

Go deeper on Aminotransferase enzyme dependent on pyridoxal phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aminotransferase enzyme dependent on pyridoxal phosphate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call